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REVIEW CURRENTOPINION Mechanisms of vascular comorbidity
in autoimmune diseases1040-8711 Copyright  2018 The A¨ a,b,c, ´ ´ b, ´ a,dGyorgy Nagy , Nora Nemeth , and Edit I BuzasPurpose of review
Persuasive statistics support the clinical observation that because of cardiovascular comorbidities patients
with inflammatory joint disease die significantly earlier despite anti-inflammatory therapy.
Recent findings
The reason for this earlier death is multifactorial and involves a combination of a complex genetic
background, environmental influences, classical cardiovascular risk factors and the impact of anti-
inflammatory therapy. We will describe the importance of several new mechanisms, especially the diverse
intercellular communication routes including extracellular vesicles and microRNAs that support the
development of cardiovascular comorbidities.
Summary
The aim of this review is to give an updated overview about the known risk factors in the development of
cardiovascular comorbidities with the latest insights about their mechanism of action. Furthermore, the
impact of newly identified risk factors and significance will be discussed.
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drugs (DMARDs), the diagnosis of rheumatoid
arthritis inevitably lead to a painful, progressive
inflammatory arthropathy with joint erosion, defor-
mation and loss-of-function. Nowadays with aggres-
sive treatment (treat-to-target strategy), low disease
activity or even remission have become realistic
goals, improving the quality of life of these patients.
Despite significant advances in treatment, patients
die significantly earlier than the general population
because of cardiovascular comorbidities, mostly in
connection with accelerated atherosclerosis [1
&
].
This clinical finding was underpinned by several
epidemiological studies, which were followed by a
new era of investigations aiming to understand the
underlying pathophysiological mechanisms of this
phenomenon. Lindhardsen et al. [2] examined the
risk of acute myocardial infarction (AMI) in rheu-
matoid arthritis and stated that the risk of AMI was
as high as the risk of AMI in patients with diabetes
mellitus. Further results were recently published by
Ruscitti et al., presenting the results of a one-year
prospective single centre study of patients suffering
from rheumatoid arthritis. They quantified the
increased risk for cardiovascular events (CVEs) anduthor(s). Published by Wolters KluweCVE and/or displaying subclinical atherosclerosis
doubled within 12 months [3]. Another epidemio-
logical study from Spain measured comorbidities in
rheumatoid arthritis patients with a mean disease
duration of 10 years and demonstrated a 51% prev-
alence of a Framingham Risk Score over 20%, result-
ing in a frequency of 5 and 1% of AMI and stroke,
respectively [4
&
].r Health, Inc. www.co-rheumatology.com
KEY POINTS
 Despite significant improvements in the treatment of
autoimmune diseases, patients die earlier than the
general population, mainly because of
cardiovascular comorbidities.
 Important new data are available about the complex
interactions of genetic and environmental risk factors.
 Emerging data support the role of extracellular vesicles
and microRNAs in the development of
cardiovascular comorbidities.
Immunopathogenesis and treatment of autoimmune diseasesWith a mean follow-up of 5.8 years in an inter-
national cohort, diverse risk factors and CVD out-
comes were collected from 5638 patients with
rheumatoid arthritis and found that a total of
70% of CVD events were attributable to classical
cardiovascular risk factors, Disease Activity Score
and seropositivity combined. This demonstrates
how important it is to closely monitor disease activ-
ity and cardiovascular risk factors in rheumatoid
arthritis patients, but it also shows the need for
defining the ‘missing’ 30% responsible for cardio-
vascular comorbidities [5].
The present review aims to summarize current
knowledge about the contributing factors for cardio-
vascular comorbidities, from the genetic background
and known cardiovascular risk factors through to the
newest research results, highlighting particularly
those related to extracellular vesicles, microRNAs
(miRNAs) and their synergy, resulting in the higher
morbidity and mortality rates in these patients.GENETIC BACKGROUND OF
CARDIOVASCULAR COMPLICATIONS IN
AUTOIMMUNE JOINT DISEASE
The investigation of the genetic background of com-
plex diseases is challenging. The search for genetic
components for comorbidities of these autoimmune
disorders (which are also of multifactorial origin) is
even more challenging. The genetic basis of auto-
immune joint disease is confirmed by classical
genetic studies, for example twin and family studies
[6]. A twin study conducted in 2000, which included
over 13000 twin pairs from Finland and the United
Kingdom, estimated a contribution of genetic fac-
tors of around 60% [7].
A large number of candidate gene studies inves-
tigated the most different genes and their single
nucleotide polymorphisms (SNP) in the develop-
ment of cardiovascular comorbidities in patients
with rheumatoid arthritis [8–10]. Starting points of
candidate gene association studies are thephysiology198 www.co-rheumatology.comand pathophysiology of genes encoding for proteins
with known function and their involvement in the
developmentof agivenphenotype.Thus, genetic loci
are selected upon their potential biological function.
There is a recent excellent summary of the results of
these studies [1
&
] showing that in addition to thewell
known HLA-DRB1 01/04 shared epitope, several
other genetic variants located inside and outside of
the HLA region on the sixth chromosome may be of
influence on the risk of cardiovascular disease (CVD)
in rheumatoid arthritis. In addition, most variants
outside the HLA region with a positive correlation to
the elevated cardiovascular risk among rheumatoid
arthritis patients on the basis of this review, are
connected to genes encoding for proteins of cells
and molecules of the immune system, including
the tumor necrosis factor (TNF) superfamily genes,
cytokines and related genes, chemokines, or adipo-
kines [1
&
]. Furthermore, correlations have also been
found with variants of genes involved in nitric oxide
synthesis [11] andvitaminD levels [12]. Finally, there
are some additional exciting potential associations
with other, seemingly unrelated genes, such as
MTHFR, important in the homocysteine plasma level
homeostasis [13].
Ten genes (CRP, HNF1A, LEPR, GCKR, NLRP3,
IL1F10, PPP1R3B, ASCL1, HNF4A, and SALL1)
known to have an impact on the serum level of
CRP in nonrheumatic Caucasians were genotyped
in rheumatoid arthritis patients. It was assessed
whether they were of influence on the development
of CVEs and subclinical atherosclerosis in this spe-
cial clinical subgroup. Interestingly, no association
could be shown between these genes and CVEs in
rheumatoid arthritis [14].CLASSICAL RISK FACTORS OF
CARDIOVASCULAR DISEASES ARE MORE
COMMON AMONG PATIENTS WITH
AUTOIMMUNE DISORDERS
Smoking
Smoking is a well known risk factor of both autoim-
mune diseases and accelerated atherosclerosis. In
autoimmune diseases, smoking was shown tomodu-
late the immune system in various ways, namely the
induction of the inflammatory response, alteration
of cytokinebalance, inductionof apoptosis, andDNA
damage resulting in the formation of anti-DNA anti-
bodies [15]. There are a variety of studies that have
addressed this area [16–18]. The harmful effect of
smoking has been described in early atherogenesis
especially on endothelial cells [19]. Effects are medi-
ated through low NO bioavailability, followed
by increased adhesion molecule expression andVolume 30  Number 2  March 2018
Role of vascular comorbidity in autoimmune diseases Nagy et al.subsequent endothelial dysfunction. A procoagulant
and inflammatory milieu is generated by the
increased adherence of platelets and macrophages.
Macrophages migrate under the endothelial cells,
take up oxidized lipoproteins and transform into
foam cells.
Several studies reported interactions between
smoking and different factors that are predictive
of the cardiovascular outcome [rheumatoid factor;
anti-citrullinated protein antibodies (ACPA) posi-
tivity, rheumatoid nodules, anti-TNF treatment,
rheumatoid cachexia] [20]. This complicates the
estimation of the extent of contribution of smoking
to cardiovascular risk in patients with rheumatoid
arthritis. Importantly, not only smoking, but also
second-hand (passive) smoking has an impact
on disease activity in women with rheumatoid
arthritis [21
&
].Insulin resistance
Despite the updated recommendations from Euro-
pean League Against Rheumatism (EULAR) for the
management of cardiovascular risk factors in
patients with inflammatory arthritis, type 2 diabetes
(T2D) is still underdiagnosed und undertreated.
Ruscitti et al. [22] claim the poor clinical response
for this as the main risk factor. A recent cross-sec-
tional study demonstrated that the prevalence of
both T2D and impaired fasting glucose (IFG) was
higher in patients with rheumatoid arthritis com-
pared with age-matched and sex-matched controls
[23]. Furthermore, they were associated with both
rheumatoid arthritis-specific features and tradi-
tional cardiovascular risk factors [23].Dyslipidaemia
Adverse changes in the lipid profile are one of the
main risk factors of cardiovascular morbidity and
mortality. However, it is not evident to which level
targeting the different lipoprotein subpopulations
reduces the risk of CVEs. In a recently published
prospective study based on data from over 50000
patients with hypertension, dyslipidaemia or diabe-
tes mellitus, an association was found between
high-density lipoprotein (HDL)-cholesterol, total/
HDL-cholesterol and triglyceride/HDL-cholesterol
ratios, and a higher risk for CVD, in contrast to
other common lipid profile biomarkers [24]. Recent
observations show that small dense low-density
lipoprotein (LDL) particles (sdLDL) are elevated
not only in diverse metabolic disorders, but also
in rheumatoid arthritis and psoriatic arthritis
(PsA) [25]. This lipoprotein subgroup is especially
important as it seems to be particularly atherogenic,
and seems to be a good predictor of significant1040-8711 Copyright  2018 The Author(s). Published by Wolters Kluwecoronary artery stenosis. This is because of its high
susceptibility to oxidation, high endothelial perme-
ability, and decreased LDL receptor affinity [26].
Sudden cardiac death is twice as common
among rheumatoid arthritis patients as in the gen-
eral population. Regarding this, the importance of
close lipid management is highlighted by the recent
results of Turk et al. [27], showing a close relation-
ship between prolonged QRS time and elevated
total cholesterol.Arterial hypertension
A study of cross-sectional design with multistage
sampling, involving 2455 Chinese hypertensive
patients, clearly demonstrated the importance
of patient compliance. The percentage of non-
compliant patients and the rate of suboptimal
blood pressure control were both above 45%. In
addition, multimorbidity was also more frequent
in these patients, accentuating the importance
of more clinical attention to this subgroup of
patients [28
&&
].
Among classical cardiovascular risk factors,
hypertension has the highest incidence and preva-
lence both in rheumatoid arthritis (74 cases per 1000
patient-years; 18.6% of patients) and psoriatic arthri-
tis (79.8 cases per 1000 patient-years; 19.9% of
patients) [29]. Not only blood pressure itself but
arterial inflammation is more prevalent in patients
with rheumatoid arthritis and is independently asso-
ciated with both traditional cardiovascular risk fac-
tors and rheumatoid arthritis-disease characteristics
[30
&&
].
Another important aspect of close cardiovascu-
lar risk management is demonstrated in a recent
analysis of retrobulbar blood flow and choroidal
thickness of rheumatoid arthritis patients, which
showed a significantly higher peak systolic velocity
of the ophthalmic and central retinal artery in rheu-
matoid arthritis patients compared with healthy
controls [31].Physical activity
Carlsson et al. stimulated peripheral blood mono-
nuclear cells from children with high versus average
physical activity. The authors found that high phys-
ical activity was associated with lower immune
reactivity toward autoantigens GAD65, HSP60,
and IA-2 and also with lower spontaneous pro-
inflammatory immune activity [32
&
].
However, physical activity in juvenile idiopathic
arthritis (JIA) patients can be a double-edged
sword as at times of acute flare, exercise may be
very painful for these patients. Also, physical activ-
ity may exacerbate underlying inflammatoryr Health, Inc. www.co-rheumatology.com 199
Immunopathogenesis and treatment of autoimmune diseasesprocesses. Through exercise, the secretion of various
hormones, miRNAs, and peptides are influenced
and it seems that muscle cell-derived IL-6 has a
central role in the fine balancing of anti-inflamma-
tory and pro-inflammatory cytokines [33].Hyperhomocysteinaemia
Taking into consideration that the risk for cardio-
vascular comorbidities is still underestimated in
patients with rheumatoid arthritis, it is thought-
provoking that in the Journal of Rheumatology in
1998, attention had already been drawn to the
importance of folic acid supplementation to pre-
vent folate deficiency and hyperhomocysteinae-
mia and, if necessary, to prevent Methotrexate
(MTX) toxicity [34]. Essouma and Noubiap [35]
emphasized the importance of the bidirectional
link between immunoinflammatory activation
and hyperhomocysteinaemia. Hyperhomocystei-
naemia may lead to nuclear kappa B enhancement
and vice versa, chronic immune activation causes
hyperhomocysteinaemia through vitamin B
(including folic acid) depletion. The authors also
underline the importance of folic acid supplemen-
tation in preventing cardiovascular complications
in rheumatoid arthritis [35]. In cutaneous lupus
erythematosus, the level of homocysteine is corre-
lated with disease severity [36]. The C677T poly-
morphism in the MTHFR gene, important in the
re-methylation of homocysteine, varies depending
on geography and ethnicity [37].Vitamin D level
The CIMESTRA trial has recently shown the impor-
tance of optimal vitamin D serum levels in patients
with rheumatoid arthritis. The study found that low
baseline vitamin D metabolite levels associate with
long-term CVEs in patients suffering from rheuma-
toid arthritis [38
&
]. Neuropathic pain is often a
therapeutic challenge in chronic inflammatory dis-
eases. In a recent cross-sectional study, patients
suffering from rheumatoid arthritis filled out the
Leeds Assessment of Neuropathic Symptoms and
Signs (LANSS) questionnaire and their serum vita-
min D levels were measured. An association was
shown between low-serum vitamin D levels and
increased neuropathic pain, which underlines
again the importance of optimal vitamin D serum
levels [39].Obstructive sleeping apnoea
A current population-based study showed that
obstructive sleep apnoea has a higher incidence in200 www.co-rheumatology.compatients with rheumatoid arthritis as compared
with age-matched and sex-matched controls. Con-
sidering the importance of obstructive sleep
apnoea in predicting the future CVD risk, it may
be important to screen patients for obstructive sleep
apnoea [40
&
].Diet
The higher risk of cardiovascular comorbidities
among patients with inflammatory joint disease
consuming higher amounts of sodium is not the
only consequence: sodium has an impact on the
Th17 pathway activation and it can, thus, promote
autoimmunity. A recent study shows an increased
sodium excretion in patients with early rheumatoid
arthritis [41]. Not only in-vitro evidence shows an
anti-inflammatory effect of trans-resveratrol, the
major cardioprotective component of red wine,
but in preclinical models of osteoarthritis and rheu-
matoid arthritis. A joint protective effect through
decreased production of pro-inflammatory and pro-
degenerative soluble factors of trans-resveratrol was
shown [42]. Fish consumption seems to be protec-
tive not only in decreasing the CVD risk through, for
example, lowering triglycerides and increasing HDL
serum levels [43], but has also been shown to impact
on rheumatoid arthritis, associated with lower dis-
ease activity [44].INFLAMMATION
Neutrophil to lymphocyte ratio is not only a reliable
marker for inflammation in neoplastic and cardio-
vascular disorders, but a recent study shows its
reliability also for disease activity in rheumatoid
arthritis [45]. Low disease activity, defined by a
disease activity score (DAS, 28) lower than
3.2 results in a reduced risk in cardiovascular com-
plication in patients suffering from rheumatoid
arthritis [46
&
]. The magnitude and period of time
of elevated CRP serum levels correlates with an
increased risk of cardiovascular complications
in rheumatoid arthritis [47]. Myocardial infarction
is one of the main complications of accelerated
atherosclerosis in rheumatoid arthritis patients
and CRP serum level is also associated with
AMI [48]. Thus, Meissner et al. declare that it is
seemingly irrelevant which DMARD is adminis-
tered but the goal must be the quickest effective
disease control.
Symmetric dimethylarginine (SDMA) and
asymmetric dimethylarginine (ADMA) emerge as
novel biomarkers of CVDs. Their levels are also
abnormal in patients with rheumatoid arthritis.
Dimitroulas et al. [49] analyzed their presence inVolume 30  Number 2  March 2018
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revealed that these molecules may promote endo-
thelial injury in rheumatoid arthritis patients as a
result of systemic inflammation during active
disease periods.DOES TREATMENT INFLUENCE
CARDIOVASCULAR RISK?
Treatment of inflammatory joint disease should
aim to reduce the cardiovascular risk accompanied
with the disease, which is best achievedwith a treat-
to-target approach [50]. This is underpinned by a
time-dependent Cox regression analysis of the Nij-
megen early rheumatoid arthritis inception cohort,
which showed that low disease activity was signifi-
cantly associated with reduced risk of first CVE
[46
&
]. The effect of glucocorticosteroids on the car-
diovascular risk is still questionable. On the one
hand, glucocorticosteroid-induced hypertension,
insulin resistance, and metabolic effects (especially
insulin resistance and obesity) increase the cardio-
vascular risk, but on the other hand, attenuating
inflammation is beneficial [51,52]. Nonsteroidal
anti-inflammatory drugs (NSAIDs) increase the risk
of CVD in the general population; diclofenac has a
similar cardiovascular risk to rofecoxib [53]. The
cardiovascular safety profile of COX2 selective
and nonselective NSAIDs in rheumatoid arthritis
and osteoarthritiswas recently published; celecoxib
was found to be noninferior to naproxen or ibupro-
fen in this study [54]. NSAIDs, especially COX2
inhibitors, increase the cardiovascular risk in rheu-
matoid arthritis [51].
Probably because of a blood pressure lowering
and anti-inflammatory effect, methotrexate therapy
seems to decrease the cardiovascular risk in rheuma-
toid arthritis [55].
Although TNF inhibitors frequently increase
the total cholesterol, triglyceride, HDL and LDL
cholesterol levels, accumulating evidence suggest
the beneficial effect of these biologicals on car-
diovascular risk [51]. Interestingly, whenever
compared with TNF inhibitors, tocilizumab is
associated with an even higher increase in blood
cholesterol and triglyceride levels [56]. A recently
published multidatabase cohort study suggests
that the cardiovascular risk of rheumatoid arthri-
tis patients treated with tofacitinib versus TNF
inhibitors is similar [57]. These observations sug-
gest that glucocorticosteroids and NSAIDs should
be tapered as soon as possible. Appropriate com-
binations of synthetic and biological DMARDs, in
addition to optimizing lipid levels and hyperten-
sion, may provide the best cardiovascular out-
come in rheumatoid arthritis.1040-8711 Copyright  2018 The Author(s). Published by Wolters KluweNEW PARTICIPANTS IN THE COMPLEX
BACKGROUND OF CARDIOVASCULAR
COMORBIDITIES IN AUTOIMMUNE
DISEASES: EXTRACELLULAR VESICLES
In addition to cytokines and chemokines, extracellu-
lar vesicles are newmediators of intercellular commu-
nication [58]. Extracellular vesicles are highly diverse,
heterogeneous, membrane-surrounded, subcellular
structures that can be found in all body fluids. Cur-
rently, there is no molecular marker or marker panel
that precisely discriminates extracellular vesicle sub-
populations; based on their size, extracellular vesicles
can be classified as small extracellular vesicles/exo-
somes (30–150nm), intermediate sized extracellular
vesicles/microvesicles/microparticles (100–1000nm)
and large extracellular vesicles such as apoptotic bod-
ies (1–5mm). Extracellular vesicles may target both
neighbouring or remote cells, and by transferring
DNA, RNA or proteins, extracellular vesicles may reg-
ulate multiple functions of target cells [58,59].
Extracellular vesicles are secreted by all human
cells; blood-derived extracellular vesicles mainly orig-
inate from platelets, red blood cells, monocytes, lym-
phocytes, granulocytes, and endothelial cells. In
addition to their broad physiological functions, extra-
cellular vesicles play a central role in the pathogenesis
of several diseases including cardiovascular and
immunological conditions [60,61]. Although the lack
of standardized isolation and characterization meth-
ods still hampers the widespread use of extracellular
vesicles as diagnostic and prognostic biomarkers, a
characteristic extracellular vesicle profile has been
described in autoimmune diseases [60,62]. Increased
levels of both phosphatidylserine-positive and phos-
phatidylserine-negativemicrovesicles,without associ-
ation with the disease activity, was recently described
in SLE [63].
Numerous observations support the multifaceted
role of extracellular vesicles in CVD as well [64
&
].
Extracellular vesicles have been claimed to promote
plaque stability [65]. Small extracellular vesicles con-
taining insulin-like growth factor 1 receptor (IGF-1R)
andmiR-29a have been found to have a cardioprotec-
tive effect in rats [66]. On the other hand, mainly
platelet-derived human microvesicles are thrombo-
genic [67]. Elevated levels of endothelial cell-derived
and platelet-derived extracellular vesicles were
observed in acute coronary syndrome [68]. Interest-
ingly, according to recently published observations,
althoughsmokingpromotedbothextracellularvesicle
release by leukocytes, platelets and endothelial cells,
and vascular inflammation, these effects were pre-
vented by red wine [69]. Extracellular vesicles may
also significantlymodulate theeffectof cytokines [70].
A highly unexpected observation was recently
found by Sodar et al. [71], namely that LDL mimicsr Health, Inc. www.co-rheumatology.com 201
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FIGURE 1. The figure demonstrates the known factors to our best current knowledge being of influence on the development of
cardiovascular comorbidities such as stroke, acute myocardial infarction or peripherial arterial disease. PAD, peripherial
arterial disease.
Immunopathogenesis and treatment of autoimmune diseasesextracellular vesicles derived from blood plasma and
may be copurified, which underlines their potential
rolewhenever examining factors contributing to the
development of CVD in rheumatic conditions/dis-
orders.
Although there is little direct evidence, these
data strongly support the potential role of extracel-
lular vesicles in vascular comorbidity of autoim-
mune diseases. Extracellular vesicles may provide
a link between inflammation and thromboembolic
risk (Fig. 1).ANOTHER NEW PARTICIPANT:
MICRORNAS
Estimates show that as high as 10–30% of protein
codinggenesare regulatedbymicro-RNAs [72],which
are small regulator RNA molecules composed of 21–
24 nucleotides. Salmena et al. [73] introduced the
term ‘competing endogenous RNAs,’ describing the
complex communication system between the differ-
ent subtypes of RNA molecules. During CD4 T-cell
activation, posttranscriptional urydylation by the
enzymes TUT4 and TUT7 are responsible for the fine
tuning of miRNA levels [74]. MiRNAs are relatively
stable molecules and their measurement is reliably
reproducible [75]. It also now known that the most
diverse illnesses are all characterized by specific
changes in the miRNA profile, which makes them a
very promising tool for diagnostic purposes [76,77].202 www.co-rheumatology.comSerum miR-210 and miR-155 levels could be
shown to be reliable biomarkers for the diagnosis
of rheumatoid arthritis [78]. There have been stud-
ies looking for miRNA biomarkers for subclinical
atherosclerosis in rheumatoid arthritis, but until
now only little or no association was found, when-
ever assessing miR-15a-5p, miR-24-3p, miR-26a-5p,
miR-125a-5p, miR-146a-5p, miR-155-5p, and miR-
223-3p [79].
An interesting link between different risk fac-
tors was found in a study measuring vitamin D
levels in SLE patients and correlating them with
certain miRNA levels in patients’ T cells. An associ-
ation between vitamin D concentrations and
measured miRNA levels (miRNA-377, miRNA-342,
miRNA-10a, miRNA-374b, miRNA-125a, and
miRNA-410) was observed – not only comparing
SLE patients with healthy controls, but also
between patients differing in their vitamin D serum
levels and also in cultured T cells from SLE patients,
wherever the correlation was dose-dependent and
time-dependent [80
&&
].COOPERATION OF DIFFERENT
MESSENGERS? EXTRACELLULAR
VESICLES TRANSPORT IMPORTANT
MICRORNAS
In atherosclerosis, Nguyen et al. [81
&&
] have demon-
strated that extracellular vesicles originating fromVolume 30  Number 2  March 2018
Table 1. List of risk factors influencing the development of cardiovascular comorbidities in inflammatory joint diseases
Factors Effect References
Genetic background
ACP1 – C haplotype Risk factor Teruel et al. [84]
CCR5D32 Protective factor Rodrı´gu´ez-Rodrı´guez et al. [85]
Chr1p13.3 – rs599839 – G allele Risk factor Lo´pez-Mejı´as et al. [86]
HLA-DRB10104 Risk factor Mattey et al. [87]
IL33 – rs3939286 – T allele Protective factor Lo´pez-Mejı´as et al. [88]
IRF5 – GTG haplotype Protective factor Garcia-Bermu´dez et al. [89]
LTA – 252GG Risk factor Panoulas et al. [90]
MHFTR – rs1801131 – C allele Risk factor Abd El-Aziz et al. [91]
MIA3 – rs17465637 – A allele Risk factor Garcia-Bermu´dez et al. [92]
MSRA – rs10903323 – G allele Risk factor Garcia-Bermu´dez et al. [93]
NFKB – rs28362491 – -94ATTG ins/del Risk factor Lo´pez-Mejı´as et al. [94]
OPG – CGA haplotype Protective factor Genre et al. [95]
SMAD3 – rs17228212 – C allele Protective factor Garcia-Bermu´dez et al. [96]
TGFB – rs1800470TC Risk factor Chen et al. [97]
TNFa – rs1800629 – A allele Risk factor Rodrı´guez-Rodrı´guez et al. [8]
VDR – GATG haplotype Risk factor Lo´pez-Mejias et al. [12]
ZC3HC1 – rs11556924 – TT genotype Risk factor Lopez-Mejias et al. [98]
Classical cardovascular risk factors
Smoking Risk factor Murphy et al. [20]
Insulin resistance Risk factor Ruscitti et al. [22]
Dyslipidaemia Risk factor Gerber et al. [25]
Arterial hypertension Risk factor Radner et al. [29], Geraldino-Pardilla et al. [30&&]
Physical activity Protecting factor Carlsson et al. [32&], Antunes et al. [33]
Hyperhomocysteinaemia Risk factor Morgan et al. [34], Essouma and Noubiap [35]
Low baseline vitamin D level Risk factor Herly et al. [38&]
Obstructive sleeping apnoe Risk factor Wilton et al. [40&]
Sodium intake Risk factor Marouen et al. [41]
Trans-resveratrol Protective factor Nguyen et al. [42]
Fish consumption Protective factor Alhassan et al. [43], Tedeschi et al. [44]
Therapy
Corticostreoids Complex effect Roubille et al. [51], van Sijl et al. [52]
NSAIDs
Celecoxib Complex effect Nissen et al. [54]
Naproxen Complex effect Nissen et al. [5]
Ibuprofen Complex effect Nissen et al. [54]
Methotrexate Protective factor Mangoni et al. [55]
TNF inhibitors Protective factor Roubille et al. [51]
Tocilizumab Complex effect Gabay et al. [56], Kim et al. [57]
New modalities
Extracellular vesicles Complex effect No publication yet
miRNAs Complex effect No publication yet
Role of vascular comorbidity in autoimmune diseases Nagy et al.atherogenic macrophages transfer certain miRNAs
(in particular miR-146a). The important role of
miRNA-126-3p and miRNA-126-5p, transferred by1040-8711 Copyright  2018 The Author(s). Published by Wolters Kluweextracellular vesicles originating from endothelial
cells after AMI, was also demonstrated by Akbar et al.
[82] and showed that these messengers promote ther Health, Inc. www.co-rheumatology.com 203
Immunopathogenesis and treatment of autoimmune diseasesrecruitment of transcriptionally activated splenic
monocytes to the heart.
Systematic characterization ofmicrovesicles and
exosomes derived from T lymphocytes of healthy
and SLE patients revealed that, depending on stim-
uli, extracellular vesicles carry a specific RNA profile
and a deregulation of miR-155, miR-34b, and miR-
34a could be shown. This again underlines the
importance of intercellular communication via
extracellular vesicles and miRNAs in autoimmune
diseases [83
&&
].CONCLUSION
Cardiovascular comorbidities of autoimmune
diseases are the result of different
contributing factors and their synergistic
effects
The present review contains numerous studies
investigating multiple independent risk factors of
cardiovascular comorbidities in autoimmune dis-
eases, focusing on conditions involving the joints.
We wish to underline the complex interactions and
the importance of their total effect on the pheno-
type discussed in this review ([84–98]; Table 1). Our
suggestion is to focus on new mechanisms emerg-
ing, especially the common intercellular commu-
nication system of extracellular vesicles and
miRNAs as no study yet considers these factors
together in the development of cardiovascular
comorbidities in patients with inflammatory
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